San Francisco, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET), based in San Francisco, is a pioneering biotech company focused on oncology . The company is developing its proprietary autologous immune-therapy approach in oncology. SNET envisions developing its strategic goals for the most effective therapies with a durable response and minimum adverse effects. The company believes that its autologous immune-therapy as a monotherapy and/or when combined with other therapies such as chemos, Immune Check Point Inhibitors, radiation and /or immuno-therapies will be a "game changer".
The National Cancer Institute in 2018 estimated 1,736,350 new cases of cancer in the US and 609,640 people died as a result of cancer. According to a 2018 report by WHO, cancer is the second leading cause of death in the world. Cancer, according to the report was responsible for an estimated 9.6 million deaths in 2018. The global growth in oncology drug market according to the IMS is expected to be between 7.5-10.5% through 2020 and the market is projected to reach $150 billion. Subject to regulatory approval, SourcingLink.net expects to capture the market share through commercialization of its products and/or through strategic partnerships with the big pharmas.
SourcingLink.net has licensed and strategically partnered with pioneering biotech and pharmaceutical companies in the rapidly emerging field of oncology for achieving its mission, goals and vision.
About SourcingLink.net:
SourcingLink.net, Inc. ("SNET") is a pioneering oncology company dedicated to developing , manufacturing and commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.
Forward-looking Statements:
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as “expect”, “believe” or “plan”, by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.